 Connection
Lisa Bero to Disclosure
This is a "connection" page, showing publications Lisa Bero has written about Disclosure.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
5.704 |
|
|
|
-
Moynihan R, Lai A, Jarvis H, Duggan G, Goodrick S, Beller E, Bero L. Undisclosed financial ties between guideline writers and pharmaceutical companies: a cross-sectional study across 10 disease categories. BMJ Open. 2019 02 05; 9(2):e025864.
Score: 0.601
-
Bero L, Grundy Q. Conflicts of Interest in Nutrition Research. JAMA. 2018 07 03; 320(1):93-94.
Score: 0.576
-
Grundy Q, Dunn AG, Bourgeois FT, Coiera E, Bero L. Prevalence of Disclosed Conflicts of Interest in Biomedical Research and Associations With Journal Impact Factors and Altmetric Scores. JAMA. 2018 01 23; 319(4):408-409.
Score: 0.559
-
Bero L. Addressing Bias and Conflict of Interest Among Biomedical Researchers. JAMA. 2017 May 02; 317(17):1723-1724.
Score: 0.532
-
Bero L. What is in a name? Nonfinancial influences on the outcomes of systematic reviews and guidelines. J Clin Epidemiol. 2014 Nov; 67(11):1239-41.
Score: 0.440
-
Krle?a-Jeri? K, Lemmens T, Reveiz L, Cuervo LG, Bero LA. Prospective registration and results disclosure of clinical trials in the Americas: a roadmap toward transparency. Rev Panam Salud Publica. 2011 Jul; 30(1):87-96.
Score: 0.355
-
Glaser BE, Bero LA. Attitudes of academic and clinical researchers toward financial ties in research: a systematic review. Sci Eng Ethics. 2005 Oct; 11(4):553-73.
Score: 0.238
-
Bero LA, Glantz S, Hong MK. The limits of competing interest disclosures. Tob Control. 2005 Apr; 14(2):118-26.
Score: 0.230
-
Boyd EA, Lipton S, Bero LA. Implementation of financial disclosure policies to manage conflicts of interest. Health Aff (Millwood). 2004 Mar-Apr; 23(2):206-14.
Score: 0.213
-
Parker L, Bero L. Managing risk from conflicts of interest in guideline development committees. BMJ. 2022 12 06; 379:e072252.
Score: 0.196
-
Moynihan R, Fabbri A, Parker L, Bero L. Mixed methods evaluation of workshops for citizen health advocates about financial conflicts of interests in healthcare. BMJ Open. 2020 05 10; 10(5):e034195.
Score: 0.164
-
Grundy Q, Mazzarello S, Bero L. A comparison of policy provisions for managing "financial" and "non-financial" interests across health-related research organizations: A qualitative content analysis. Account Res. 2020 05; 27(4):212-237.
Score: 0.163
-
Bero LA. Accepting commercial sponsorship. Disclosure helps--but is not a panacea. BMJ. 1999 Sep 11; 319(7211):653-4.
Score: 0.157
-
Parker L, Karanges EA, Bero L. Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study. BMJ Open. 2019 02 19; 9(2):e024928.
Score: 0.151
-
Bero LA, Grundy Q. Not All Influences on Science Are Conflicts of Interest. Am J Public Health. 2018 05; 108(5):632-633.
Score: 0.142
-
Bero LA. Disclosure policies for gifts from industry to academic faculty. JAMA. 1998 Apr 01; 279(13):1031-2.
Score: 0.142
-
Fabbri A, Grundy Q, Mintzes B, Swandari S, Moynihan R, Walkom E, Bero LA. A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia. BMJ Open. 2017 06 30; 7(6):e016701.
Score: 0.134
-
Nguyen NY, Bero L. Medicaid drug selection committees and inadequate management of conflicts of interest. JAMA Intern Med. 2013 Mar 11; 173(5):338-43.
Score: 0.100
-
Roseman M, Turner EH, Lexchin J, Coyne JC, Bero LA, Thombs BD. Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. BMJ. 2012 Aug 16; 345:e5155.
Score: 0.096
-
Roseman M, Milette K, Bero LA, Coyne JC, Lexchin J, Turner EH, Thombs BD. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA. 2011 Mar 09; 305(10):1008-17.
Score: 0.087
-
Robertson J, Moynihan R, Walkom E, Bero L, Henry D. Mandatory disclosure of pharmaceutical industry-funded events for health professionals. PLoS Med. 2009 Nov; 6(11):e1000128.
Score: 0.079
-
Boyd EA, Bero LA. Defining financial conflicts and managing research relationships: an analysis of university conflict of interest committee decisions. Sci Eng Ethics. 2007 Dec; 13(4):415-35.
Score: 0.069
-
Bero LA. Managing financial conflicts of interest in research. J Am Coll Dent. 2005; 72(2):4-9.
Score: 0.057
-
Lipton S, Boyd EA, Bero LA. Conflicts of interest in academic research: policies, processes, and attitudes. Account Res. 2004 Apr-Jun; 11(2):83-102.
Score: 0.054
-
Boyd EA, Cho MK, Bero LA. Financial conflict-of-interest policies in clinical research: issues for clinical investigators. Acad Med. 2003 Aug; 78(8):769-74.
Score: 0.051
-
Pokorny AMJ, Bero LA, Moynihan R, Mintzes BJ. Industry payments to Australian medical oncologists and clinical haematologists: a cross-sectional analysis of publicly available disclosures. Intern Med J. 2021 Nov; 51(11):1816-1824.
Score: 0.045
-
Fabbri A, Nejstgaard CH, Grundy Q, Bero L, Dunn AG, Mohammad A, Mintzes B. Association Between Conflicts of Interest and Authors' Positions on Harms of Varenicline: a Cross-Sectional Analysis. J Gen Intern Med. 2022 02; 37(2):290-297.
Score: 0.044
-
Robertson J, Walkom E, Moynihan R, Bero L, Henry D. Pharmaceutical industry funding of educational events for pharmacists in Australia: an analysis of data from the first 6 months of a mandatory disclosure programme. Int J Pharm Pract. 2010 Apr; 18(2):88-92.
Score: 0.020
-
Moynihan R, Bero L, Ross-Degnan D, Henry D, Lee K, Watkins J, Mah C, Soumerai SB. Coverage by the news media of the benefits and risks of medications. N Engl J Med. 2000 Jun 01; 342(22):1645-50.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|